Do analysts recommend CSBR or SIGA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CSBR or SLN?

Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 707.04%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Do analysts rate CSBR or ORGO?

Organogenesis has a consensus price target of $5.75, suggesting a potential upside of 145.20%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts clearly believe Organogenesis is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Organogenesis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend CSBR or PRLD?

Prelude Therapeutics has a consensus price target of $7.67, indicating a potential upside of 85.19%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prelude Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts prefer CSBR or SRZN?

Surrozen has a consensus price target of $42.00, indicating a potential upside of 85.25%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Surrozen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Champions Oncology (CSBR) Competitors

$6.29 -0.05 (-0.79%)

As of 03:17 PM Eastern

Compare

CSBR vs. SIGA, SLN, ORGO, PRLD, and SRZN

Should you buy Champions Oncology stock or one of its competitors? MarketBeat compares Champions Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Champions Oncology include Siga Technologies (SIGA), Silence Therapeutics (SLN), Organogenesis (ORGO), Prelude Therapeutics (PRLD), and Surrozen (SRZN). These companies are all part of the "med - drugs" industry.

How does Champions Oncology compare to Siga Technologies?

Champions Oncology (NASDAQ:CSBR) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Champions Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Siga Technologies has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.53	$4.70M	-$0.16	N/A
Siga Technologies	$94.57M	3.26	$23.28M	$0.27	15.94

In the previous week, Siga Technologies had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for Siga Technologies and 0 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat Siga Technologies' score of 1.87 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Very Positive
Siga Technologies	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by insiders. Comparatively, 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Siga Technologies has a net margin of 21.58% compared to Champions Oncology's net margin of -3.94%. Siga Technologies' return on equity of 10.60% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Siga Technologies	21.58%	10.60%	8.94%

Summary

Siga Technologies beats Champions Oncology on 11 of the 13 factors compared between the two stocks.

How does Champions Oncology compare to Silence Therapeutics?

Champions Oncology (NASDAQ:CSBR) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Champions Oncology has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Champions Oncology has higher revenue and earnings than Silence Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.53	$4.70M	-$0.16	N/A
Silence Therapeutics	$560K	574.89	-$88.61M	-$1.59	N/A

Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 707.04%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Champions Oncology has a net margin of -3.94% compared to Silence Therapeutics' net margin of -8,943.86%. Champions Oncology's return on equity of -57.31% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

In the previous week, Silence Therapeutics had 3 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Silence Therapeutics and 0 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat Silence Therapeutics' score of 0.62 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Very Positive
Silence Therapeutics	Positive

Summary

Silence Therapeutics beats Champions Oncology on 9 of the 17 factors compared between the two stocks.

How does Champions Oncology compare to Organogenesis?

Champions Oncology (NASDAQ:CSBR) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Organogenesis has a consensus price target of $5.75, suggesting a potential upside of 145.20%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts clearly believe Organogenesis is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Organogenesis has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.53	$4.70M	-$0.16	N/A
Organogenesis	$564.17M	0.53	$37.03M	-$0.19	N/A

Organogenesis has a net margin of -0.84% compared to Champions Oncology's net margin of -3.94%. Organogenesis' return on equity of 9.63% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Organogenesis	-0.84%	9.63%	4.76%

Champions Oncology has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Organogenesis had 2 more articles in the media than Champions Oncology. MarketBeat recorded 2 mentions for Organogenesis and 0 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat Organogenesis' score of 1.10 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Very Positive
Organogenesis	Positive

Summary

Organogenesis beats Champions Oncology on 12 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Prelude Therapeutics?

Champions Oncology (NASDAQ:CSBR) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Prelude Therapeutics has a consensus price target of $7.67, indicating a potential upside of 85.19%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Champions Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Prelude Therapeutics had 2 more articles in the media than Champions Oncology. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat Prelude Therapeutics' score of 0.94 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Very Positive
Prelude Therapeutics	Positive

Prelude Therapeutics has a net margin of 0.00% compared to Champions Oncology's net margin of -3.94%. Champions Oncology's return on equity of -57.31% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Champions Oncology has higher revenue and earnings than Prelude Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.53	$4.70M	-$0.16	N/A
Prelude Therapeutics	$12.14M	27.16	-$99.50M	-$1.00	N/A

Summary

Prelude Therapeutics beats Champions Oncology on 10 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Surrozen?

Champions Oncology (NASDAQ:CSBR) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by company insiders. Comparatively, 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Champions Oncology has a net margin of -3.94% compared to Surrozen's net margin of -4,810.50%. Champions Oncology's return on equity of -57.31% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

Champions Oncology has higher revenue and earnings than Surrozen. Champions Oncology is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.53	$4.70M	-$0.16	N/A
Surrozen	$3.48M	75.64	-$242.03M	-$37.59	N/A

In the previous week, Surrozen had 3 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Surrozen and 0 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.91 beat Surrozen's score of 0.93 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Very Positive
Surrozen	Positive

Champions Oncology has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Surrozen has a consensus price target of $42.00, indicating a potential upside of 85.25%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Surrozen beats Champions Oncology on 9 of the 17 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSBR vs. The Competition

Export

Metric	Champions Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$86.81M	$2.95B	$6.46B	$12.25B
Dividend Yield	N/A	1.76%	2.66%	5.66%
P/E Ratio	-39.06	18.52	23.96	24.45
Price / Sales	1.53	305.28	519.37	138.35
Price / Cash	14.17	55.88	27.48	37.92
Price / Book	23.30	3.99	10.58	6.77
Net Income	$4.70M	$75.79M	$3.56B	$337.21M
7 Day Performance	5.54%	1.29%	0.43%	2.12%
1 Month Performance	1.45%	-0.58%	1.70%	3.99%
1 Year Performance	-18.42%	20.45%	24.68%	28.92%

Champions Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSBR Champions Oncology	0.5706 of 5 stars	$6.29 -0.8%	N/A	-18.2%	$86.81M	$56.94M	N/A	143	Positive News
SIGA Siga Technologies	0.5785 of 5 stars	$4.29 -0.7%	N/A	-31.8%	$309.85M	$94.57M	15.89	40	Positive News
SLN Silence Therapeutics	2.5638 of 5 stars	$6.41 +0.6%	$55.00 +758.0%	+31.3%	$300.88M	$560K	N/A	100
ORGO Organogenesis	2.8079 of 5 stars	$2.33 +4.0%	$5.75 +146.8%	-21.5%	$288.23M	$564.17M	N/A	950	News Coverage Positive News
PRLD Prelude Therapeutics	4.2057 of 5 stars	$3.66 +4.6%	$7.67 +109.5%	+364.5%	$278.76M	$12.14M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Champions Oncology (CSBR) Competitors

CSBR vs. SIGA, SLN, ORGO, PRLD, and SRZN

How does Champions Oncology compare to Siga Technologies?

Summary

How does Champions Oncology compare to Silence Therapeutics?

Summary

How does Champions Oncology compare to Organogenesis?

Summary

How does Champions Oncology compare to Prelude Therapeutics?

Summary

How does Champions Oncology compare to Surrozen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Champions Oncology (CSBR) Competitors

CSBR vs. SIGA, SLN, ORGO, PRLD, and SRZN

How does Champions Oncology compare to Siga Technologies?

Which has more risk & volatility, CSBR or SIGA?

Which has stronger earnings & valuation, CSBR or SIGA?

Does the media favor CSBR or SIGA?

Do analysts recommend CSBR or SIGA?

Do institutionals and insiders have more ownership in CSBR or SIGA?

Is CSBR or SIGA more profitable?

Summary

How does Champions Oncology compare to Silence Therapeutics?

Do insiders & institutionals have more ownership in CSBR or SLN?

Which has more volatility and risk, CSBR or SLN?

Which has higher valuation and earnings, CSBR or SLN?

Do analysts recommend CSBR or SLN?

Is CSBR or SLN more profitable?

Does the media favor CSBR or SLN?

Summary

How does Champions Oncology compare to Organogenesis?

Do analysts rate CSBR or ORGO?

Which has higher earnings and valuation, CSBR or ORGO?

Is CSBR or ORGO more profitable?

Which has more risk and volatility, CSBR or ORGO?

Do institutionals and insiders hold more shares of CSBR or ORGO?

Does the media favor CSBR or ORGO?

Summary

How does Champions Oncology compare to Prelude Therapeutics?

Do analysts recommend CSBR or PRLD?

Which has more volatility and risk, CSBR or PRLD?

Do institutionals & insiders believe in CSBR or PRLD?

Does the media prefer CSBR or PRLD?

Is CSBR or PRLD more profitable?

Which has stronger earnings & valuation, CSBR or PRLD?

Summary

How does Champions Oncology compare to Surrozen?

Do insiders & institutionals believe in CSBR or SRZN?

Is CSBR or SRZN more profitable?

Which has better valuation & earnings, CSBR or SRZN?

Does the media refer more to CSBR or SRZN?

Which has more risk and volatility, CSBR or SRZN?

Do analysts prefer CSBR or SRZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools